0001140361-24-024125.txt : 20240502
0001140361-24-024125.hdr.sgml : 20240502
20240502181923
ACCESSION NUMBER: 0001140361-24-024125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240502
DATE AS OF CHANGE: 20240502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: USMAN NASSIM
CENTRAL INDEX KEY: 0001206872
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51173
FILM NUMBER: 24910168
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001124105
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 562020050
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (619) 949-3681
MAIL ADDRESS:
STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20150820
FORMER COMPANY:
FORMER CONFORMED NAME: TARGACEPT INC
DATE OF NAME CHANGE: 20000919
4
1
form4.xml
FORM 4
X0508
4
2024-05-01
0001124105
GYRE THERAPEUTICS, INC.
GYRE
0001206872
USMAN NASSIM
C/O GYRE THERAPEUTICS, INC.
12770 HIGH BLUFF DRIVE, SUITE 150
SAN DIEGO
CA
92130
true
true
Common Stock
2024-05-01
4
M
0
20000
6.93
A
21636
D
Common Stock
2024-05-01
4
S
0
14900
13.86
D
6736
D
Common Stock
2024-05-01
4
S
0
5000
14.9
D
1736
D
Common Stock
2024-05-01
4
S
0
100
15.63
D
1636
D
Common Stock
563
I
By The Usman Family Trust
Common Stock
77
I
By Nassim Usman IRA
Stock Option (Right to Buy)
6.93
2024-05-01
4
M
0
20000
0
D
2033-10-31
Common Stock
20000
281652
D
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.32. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
This option is vested in full.
/s/ Ruoyu Chen, as attorney-in-fact for Nassim Usman
2024-05-02